Engineered Neuroblastoma Cellular Immunotherapy (ENCIT)-01
0-9 years 10-17 years 18-26 years
Patient Derived CD171 specific CAR T cells expressing EGFRt
Condition: Neuroblastoma, Ganglioneuroblastoma
Patients with recurrent or refractory neuroblastoma are resistance to conventional chemotherapy. For this reason, the investigators are attempting to use T cells obtained directly from the patient, which can be genetically modified to express a chimeric antigen receptor (CAR). The CAR enables the T cell to recognize and kill the neuroblastoma cell through the recognition of CD171, a protein expressed of the surface of the neuroblastoma cell in patients with neuroblastoma. This is a phase 1 study designed to determine the maximum tolerated dose of the CAR+ T cells.